These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 37272890)
21. The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome. Park HJ; Ryu D; Parmar M; Giasson BI; McFarland NR PLoS One; 2017; 12(9):e0184262. PubMed ID: 28877262 [TBL] [Abstract][Full Text] [Related]
22. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy. Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358 [TBL] [Abstract][Full Text] [Related]
23. Oligodendrocytes Prune Axons Containing α-Synuclein Aggregates In Vivo: Lewy Neurites as Precursors of Glial Cytoplasmic Inclusions in Multiple System Atrophy? De Nuccio F; Kashyrina M; Serinelli F; Laferrière F; Lofrumento DD; De Giorgi F; Ichas F Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830639 [TBL] [Abstract][Full Text] [Related]
24. Comparing alpha-synuclein-interactomes between multiple systems atrophy and Parkinson's disease reveals unique and shared pathological features. Choi SG; Tittle T; Barot R; Betts D; Gallagher J; Kordower JH; Chu Y; Killinger BA bioRxiv; 2024 Sep; ():. PubMed ID: 39345456 [TBL] [Abstract][Full Text] [Related]
26. Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models. Drobny A; Boros FA; Balta D; Prieto Huarcaya S; Caylioglu D; Qazi N; Vandrey J; Schneider Y; Dobert JP; Pitcairn C; Mazzulli JR; Zunke F Transl Neurodegener; 2023 Jun; 12(1):31. PubMed ID: 37312133 [TBL] [Abstract][Full Text] [Related]
27. Alpha-synuclein-associated changes in PINK1-PRKN-mediated mitophagy are disease context dependent. Hou X; Chen TH; Koga S; Bredenberg JM; Faroqi AH; Delenclos M; Bu G; Wszolek ZK; Carr JA; Ross OA; McLean PJ; Murray ME; Dickson DW; Fiesel FC; Springer W Brain Pathol; 2023 Sep; 33(5):e13175. PubMed ID: 37259617 [TBL] [Abstract][Full Text] [Related]
28. RT-QuIC and Related Assays for Detecting and Quantifying Prion-like Pathological Seeds of α-Synuclein. Srivastava A; Alam P; Caughey B Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454165 [TBL] [Abstract][Full Text] [Related]
29. The GTPase Rab27b regulates the release, autophagic clearance, and toxicity of α-synuclein. Underwood R; Wang B; Carico C; Whitaker RH; Placzek WJ; Yacoubian TA J Biol Chem; 2020 Jun; 295(23):8005-8016. PubMed ID: 32350025 [TBL] [Abstract][Full Text] [Related]
30. Unexpected Implication of SRP and AGO2 in Parkinson's Disease: Involvement in Alpha-Synuclein Biogenesis. Hernandez SM; Tikhonova EB; Baca KR; Zhao F; Zhu X; Karamyshev AL Cells; 2021 Oct; 10(10):. PubMed ID: 34685771 [TBL] [Abstract][Full Text] [Related]
31. Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology. Teil M; Dovero S; Bourdenx M; Arotcarena ML; Camus S; Porras G; Thiolat ML; Trigo-Damas I; Perier C; Estrada C; Garcia-Carrillo N; Morari M; Meissner WG; Herrero MT; Vila M; Obeso JA; Bezard E; Dehay B Brain; 2022 Apr; 145(3):1001-1017. PubMed ID: 35285474 [TBL] [Abstract][Full Text] [Related]
32. Phosphatidylinositol-3,4,5-trisphosphate interacts with alpha-synuclein and initiates its aggregation and formation of Parkinson's disease-related fibril polymorphism. Choong CJ; Aguirre C; Kakuda K; Beck G; Nakanishi H; Kimura Y; Shimma S; Nabekura K; Hideshima M; Doi J; Yamaguchi K; Nakajima K; Wadayama T; Hayakawa H; Baba K; Ogawa K; Takeuchi T; Badawy SMM; Murayama S; Nagano S; Goto Y; Miyanoiri Y; Nagai Y; Mochizuki H; Ikenaka K Acta Neuropathol; 2023 May; 145(5):573-595. PubMed ID: 36939875 [TBL] [Abstract][Full Text] [Related]
33. Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies. Kawahata I; Finkelstein DI; Fukunaga K Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682892 [TBL] [Abstract][Full Text] [Related]
34. Modulation of α-synuclein in vitro aggregation kinetics by its alternative splice isoforms. Röntgen A; Toprakcioglu Z; Tomkins JE; Vendruscolo M Proc Natl Acad Sci U S A; 2024 Feb; 121(7):e2313465121. PubMed ID: 38324572 [TBL] [Abstract][Full Text] [Related]
35. Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α-synuclein accumulation in Parkinson's disease. Er S; Airavaara M Biochem Soc Trans; 2023 Feb; 51(1):245-257. PubMed ID: 36794783 [TBL] [Abstract][Full Text] [Related]
36. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Schell H; Hasegawa T; Neumann M; Kahle PJ Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424 [TBL] [Abstract][Full Text] [Related]
37. Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway. Park JH; Burgess JD; Faroqi AH; DeMeo NN; Fiesel FC; Springer W; Delenclos M; McLean PJ Mol Neurodegener; 2020 Jan; 15(1):5. PubMed ID: 31931835 [TBL] [Abstract][Full Text] [Related]
38. Carboxy-terminal truncations of mouse α-synuclein alter aggregation and prion-like seeding. Sorrentino ZA; Xia Y; Gorion KM; Hass E; Giasson BI FEBS Lett; 2020 Apr; 594(8):1271-1283. PubMed ID: 31912891 [TBL] [Abstract][Full Text] [Related]